Physician profile
Bella Zubkov
NPI 1083607386
$4,321.10
in general payments reported to CMS, 2019-2025
23 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $159 · 2021: $373 · 2022: $568 · 2023: $738 · 2024: $1,062 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,866.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,334.44 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $435.05 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $338.84 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $300.01 | 2020-2025 | Tremfya |
| Galderma Laboratories, L.P. | $284.54 | 2022-2025 | Nemluvio, Dysport |
| Dermavant Sciences, INC. | $274.11 | 2022-2024 | Vtama |
| Ucb, INC. | $179.80 | 2023-2024 | Bimzelx, Cimzia |
| Pfizer INC. | $159.10 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $157.18 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $144.08 | 2021-2024 | Dupixent |
| Lilly USA, LLC | $108.41 | 2024-2025 | Ebglyss, Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $95.86 | 2019-2025 | |
| Almirall LLC | $69.22 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $68.69 | 2023-2024 | Zoryve |
| Incyte Corporation | $62.94 | 2022-2023 | Opzelura |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $58.25 | 2025 | Vtama |
| Leo Pharma INC. | $56.55 | 2025 | Anzupgo, Adbry |
| Prugen, INC. Pharmaceuticals | $53.81 | 2020 | |
| Merz North America, INC. | $41.26 | 2024 | |
| Botanix Sb INC | $38.72 | 2025 | Sofdra |
| Lnhc, INC | $20.92 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.68 | 2024 | Spevigo |
| Mayne Pharma Commercial LLC | $19.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bella Zubkov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.